<DOC>
	<DOCNO>NCT00002931</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together bone marrow transplantation peripheral stem cell transplantation work treat patient relapsed germ cell cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Relapsed Germ Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Estimate antitumor activity 2 course paclitaxel carboplatin regimen autologous stem cell rescue patient relapsed germ cell cancer . - Evaluate toxic effect paclitaxel , carboplatin etoposide ( VP-16 ) stem cell support follow paclitaxel , carboplatin ifosfamide stem cell support patient . OUTLINE : Patients receive filgrastim ( G-CSF ) SC IV 4 day prior peripheral blood stem cell ( PBSC ) apheresis . Autologous bone marrow harvest perform adequate stem cell collect . Patients receive course 1 high-dose chemotherapy begin day -7 paclitaxel IV 24 hour . On day -6 -4 , patient receive etoposide IV 2 hour carboplatin ( CBDCA ) IV 30 minute 3 time daily . Following 2 3 week recovery , second course chemotherapy begin day -7 , consist paclitaxel IV 24 hour , CBDCA ifosfamide day -6 -4 . Reinfusion PBSC marrow begin day -2 course 1 2 . In addition , G-CSF IV give twice day 3 consecutive postnadir day granulocytes least 1000/mm^3 maintain . On day 0 , stem cell without bone marrow product administer . Surgery may perform course 2 indicated . PROJECTED ACCRUAL : The expected accrual rate 12 patient per year 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Evaluable germ cell cancer ( measurable radiographic study and/or serum tumor marker elevation ) curable standard salvage therapy OR viable cancer resection postchemotherapy residual mass either intermediate high risk category Bidimensionally measurable disease measurement perform within 21 day study entry Tumor marker ( alphafetoprotein , lactate dehydrogenase , betahuman chorionic gonadotropin ) study perform within 7 day prior study entry PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 120,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.6 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) No active hepatitis cirrhosis Renal : Creatinine clearance least 70 mL/min Cardiovascular : Ejection fraction ( MUGA echocardiogram ) normal No EKG evidence active cardiac disease ( arrhythmias , ischemia ) would contraindicate etoposide paclitaxel study treatment Pulmonary : PaO_2 least 70 mm Hg FEV_1 least 2 L 75 % No history bleomycin associate serious lung disease Neurologic : No steroid glucocorticoid treatment patient CNS metastatic disease ; least 1 month stable postradiotherapy neurological status seizure free ; prior seizure , least 1 month therapeutic anticonvulsant level prior study Prior peripheral neuropathy require consultation principal investigator Other : No significant active medical illness precluding study survival Not HIV positive No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer No prior hematologic malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow stem cell rescue highdose chemotherapy Chemotherapy : Prior chemotherapy allow , exclude highdose therapy bone marrow stem cell rescue No prior paclitaxel Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy study Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>adult teratoma</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>ovarian immature teratoma</keyword>
	<keyword>ovarian mature teratoma</keyword>
	<keyword>ovarian monodermal highly specialized teratoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
</DOC>